Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Down 40.3% in March

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 4,300 shares, a decrease of 40.3% from the February 28th total of 7,200 shares. Based on an average daily trading volume, of 8,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.0% of the company's stock are sold short.

Adlai Nortye Stock Up 6.5 %

Shares of NASDAQ ANL traded up $0.13 during mid-day trading on Wednesday, hitting $2.14. The company had a trading volume of 104 shares, compared to its average volume of 12,341. The business's 50-day simple moving average is $2.20 and its 200 day simple moving average is $2.22. Adlai Nortye has a 1-year low of $1.85 and a 1-year high of $17.48.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.